Mainz Biomed Q1 2023 Earnings Report $6.68 +1.91 (+40.04%) (As of 12/20/2024 05:40 PM ET) Earnings HistoryForecast Mainz Biomed EPS ResultsActual EPS-$18.00Consensus EPS -$18.80Beat/MissBeat by +$0.80One Year Ago EPSN/AMainz Biomed Revenue ResultsActual Revenue$0.25 millionExpected Revenue$0.18 millionBeat/MissBeat by +$70.00 thousandYoY Revenue GrowthN/AMainz Biomed Announcement DetailsQuarterQ1 2023Date5/16/2023TimeN/AConference Call ResourcesMYNZ Earnings History First JFK… next Elon? (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Mainz Biomed Earnings HeadlinesMainz Biomed partners with Quest for colorectal cancer screening testDecember 21 at 11:55 PM | msn.comMainz Biomed, Quest Diagnostics To Commercialize NextGen Colorectal Cancer Screening Test; Stock UpDecember 20 at 1:01 AM | markets.businessinsider.comFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.December 22, 2024 | Porter & Company (Ad)Mainz Biomed forms agreement with Quest DiagnosticsDecember 20 at 1:01 AM | markets.businessinsider.comMainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer Screening TestDecember 19 at 8:51 AM | quiverquant.comQuest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.December 19 at 8:51 AM | benzinga.comSee More Mainz Biomed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mainz Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mainz Biomed and other key companies, straight to your email. Email Address About Mainz BiomedMainz Biomed (NASDAQ:MYNZ) N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.View Mainz Biomed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
